Search Results
-
Post
Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates
...this may prevent or temporarily interfere with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and...
-
Post
Novocure Reports 2015 Operating Statistics and Financial Results
...respectively. Approximately 97 million Americans now have health coverage from payers that have issued positive coverage policies for Optune. Received Japanese Ministry of Health, Labour and Welfare approval of Optune...
-
Post
Novocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting
...States, Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). In the United States, Optune with temozolomide is indicated...
-
Post
Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update
...physician certified to treat patients with Optune for a patient not previously on Optune. Orders to renew or extend treatment are not included in this total. “With more than 1,800...
-
Post
Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology
...your doctor whether this may prevent or temporarily interfere with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications,...
-
Post
Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston
...interfere with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. Forward-Looking Statements In addition...
-
Post
Novocure Reports First Quarter 2016 Financial Results and Provides Company Update
...U.S. Food and Drug Administration (FDA) approval of Optune for the treatment of newly diagnosed glioblastoma (GBM), increased commercial activities in Germany, and enhanced awareness of Optune following the December...
-
Post
Novocure Reports Third Quarter 2015 Operating and Financial Results
FDA approved Optune™ in combination with temozolomide for the treatment of newly diagnosed glioblastoma on October 5, 2015 CE Mark was placed on the second generation Optune system. First patients...
-
Post
Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma
...with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. Patients should only use Optune...
-
Post
Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology
...interfere with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. Patients should only use...